Purpose To determine whether thyroid-stimulating hormone level≥ 30 mU/L is necessary
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …

Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for
initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma …

Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

Objective Remnant thyroid ablation is crucial in the management of patients with
differentiated thyroid cancer. However, the optimal dose of radioactive 131 I for ablation is …

Purpose: Radioiodine (131I) thyroid remnant ablation is an important treatment of
differentiated thyroid carcinoma (DTC) and various factors affecting its efficacy have been …

Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly
performed in the management of patients with differentiated thyroid cancer. Although many …

[en] This study was performed under the auspices of IAEA project (i) to evaluate the efficacy
of low (50 mCi) vs. high (100 mCi) dose I-131 for post operative remnant ablation in …

Purpose The aim of this study was to evaluate the efficacy of post-operative radioiodine
ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in …

Objective Is to investigate possible factors predicting success of ablation for 3700 MBq
radioactive iodine 131 in patients with differentiated thyroid cancer (DTC) following near …

Background: Radioiodine (131I) remnant ablation (RRA) has become a key step in the
postoperative treatment of differentiated thyroid cancer (DTC). However, inadequate or …